CLL

Emavusertib + Zanubrutinib Study Targets CLL Anticancer Activity

The study aims to evaluate the anticancer activity of emavusertib combined with zanubrutinib in CLL patients.

BGB-16673 Study Initiated for R/R CLL/SLL vs. Investigator's Choice

A study has been launched to evaluate BGB-16673 against standard treatments in R/R CLL/SLL patients previously treated with cBTKis.

Phase 2 Study of Mosunetuzumab in CLL Patients Post-BTKi Treatment

A Phase 2 study is underway to evaluate the efficacy of mosunetuzumab in CLL patients with detectable disease after BTKi treatment.

Phase II Trial of Nemtabrutinib with CAR T-cell Therapy in Relapsed/Refractory CLL/SLL

A phase II trial is investigating the efficacy of combining nemtabrutinib with lisocabtagene maraleucel in patients with relapsed/refractory CLL/SLL.

Natural History Study of MBL and CLL/SLL to Identify Disease Progression Markers

A natural history study is being conducted to investigate the clinical and molecular aspects of MBL, CLL/SLL, and related lymphomas.

BeOne Medicines Initiates Study of BGB-16673 in CLL/SLL Patients Post-BTK and BCL2 Inhibitor Treatment

A clinical trial is underway to assess the efficacy and safety of BGB-16673 versus standard treatments in CLL/SLL patients previously treated with BTK and BCL2 inhibitors.

AstraZeneca Evaluates Surovatamig for CLL/SLL Consolidation Therapy

AstraZeneca is conducting a trial to assess the safety and efficacy of Surovatamig as consolidation therapy in CLL/SLL patients with unmutated IGHV.

Nurix Therapeutics initiates NX-5948 study for relapsed CLL/SLL post-BTK and BCL-2 therapy

Nurix Therapeutics is conducting a trial for NX-5948 in patients with relapsed/refractory CLL/SLL who have previously been treated with BTK and BCL-2 inhibitors.

Phase III Trial Compares Ibrutinib/Rituximab vs. Chemo in CLL/SLL

A phase III trial is evaluating the efficacy of ibrutinib and rituximab against standard chemotherapy in untreated CLL/SLL patients.

Phase II Trial of MRD-Guided Zanubrutinib and Sonrotoclax in High-Risk CLL/SLL Patients

A phase II clinical trial is underway to evaluate the efficacy and safety of zanubrutinib combined with sonrotoclax in treatment-naïve high-risk CLL/SLL patients.

Lilly's Jaypirca recommended for EU approval in CLL across all therapy lines

The CHMP has issued a positive opinion for Lilly's Jaypirca (pirtobrutinib) for adults with CLL.

Lilly to present positive Phase 3 results for pirtobrutinib in CLL at EHA 2026

Phase III Trial of Early Treatment in High-Risk CLL/SLL Shows Promise

The EVOLVE CLL/SLL study is comparing early versus delayed treatment with venetoclax and obinutuzumab in high-risk CLL/SLL patients.

Nemtabrutinib Study vs Ibrutinib/Acalabrutinib in 1L CLL/SLL Initiated

A study is underway to evaluate nemtabrutinib against ibrutinib or acalabrutinib in treatment-naive CLL/SLL patients.

Study Evaluates Outcomes After Discontinuation of BTK Inhibitors in CLL Patients

A Phase II study is assessing the outcomes of stopping BTK inhibitor therapy in CLL patients in remission for over two years.

Lilly's Jaypirca shows 45% reduction in disease progression risk in CLL/SLL

Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax regimen in previously treated CLL/SLL patients.